Gri Bio, INC S-1 registration statements

GRI Bio, Inc. amended its engagement agreement with H.C. Wainwright & Co., LLC, extending the term for capital raising activities and removing the right of first refusal.

GRI Bio, Inc. announces a new public offering of common stock and warrants to raise up to $10 million, alongside positive topline Phase 2a clinical trial results for its lead IPF candidate, GRI-0621, despite ongoing financial challenges and Nasdaq non-compliance.

GRI Bio launches a public offering of common stock and warrants, aiming to raise capital for its clinical-stage biopharmaceutical initiatives.

GRI Bio, Inc. unveils a public offering of common stock and warrants to fuel its clinical-stage biopharmaceutical endeavors.

GRI Bio is launching a public offering to sell shares of common stock, pre-funded warrants, and accompanying warrants to raise capital for working capital, product development, and general corporate purposes.

GRI Bio aims to raise capital to fund operations and development through a public offering of common stock, pre-funded warrants, and accompanying warrants.

GRI Bio, a clinical-stage biopharmaceutical company, files an S-1 registration statement for a public offering of common stock and warrants to fund its clinical programs and address Nasdaq's listing requirements.

GRI Bio launches a public offering of common stock and warrants aiming to raise $8 million for clinical trials and Nasdaq compliance.

GRI Bio launches a public offering of common stock and warrants to raise up to $8 million as it faces Nasdaq listing deficiencies and aims to fund clinical trials.